Explore

Trendline Trendline
Infex Therapeutics Advances in Bronchiectasis Treatment with Promising Trial Results

Infex Therapeutics Advances in Bronchiectasis Treatment with Promising Trial Results

Infex Therapeutics Advances in Bronchiectasis Treatment with Promising Trial Results
Trendline Trendline
Verdiva Bio to Present Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio to Present Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio to Present Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions
Trendline Trendline
OpenBind Introduces AI Model to Revolutionize Drug Discovery

OpenBind Introduces AI Model to Revolutionize Drug Discovery

OpenBind Introduces AI Model to Revolutionize Drug Discovery
Trendline Trendline
OpenBind Consortium Launches AI Model to Revolutionize Drug Discovery

OpenBind Consortium Launches AI Model to Revolutionize Drug Discovery

OpenBind Consortium Launches AI Model to Revolutionize Drug Discovery
Trendline Trendline
Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform
Trendline Trendline
BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment

BioMarin Faces Setback with Phase 3 Trial Failure in Rare Disease Treatment
Trendline Trendline
Savara Presents Long-Term Data on Molgramostim for Rare Lung Disease at ATS Conference

Savara Presents Long-Term Data on Molgramostim for Rare Lung Disease at ATS Conference

Savara Presents Long-Term Data on Molgramostim for Rare Lung Disease at ATS Conference
Trendline Trendline
Savara Reports Positive Exercise Capacity Data in Phase 3 Trial for aPAP Treatment

Savara Reports Positive Exercise Capacity Data in Phase 3 Trial for aPAP Treatment

Savara Reports Positive Exercise Capacity Data in Phase 3 Trial for aPAP Treatment
Trendline Trendline
GenSight Biologics to Discuss Strategic Priorities at General Meeting

GenSight Biologics to Discuss Strategic Priorities at General Meeting

GenSight Biologics to Discuss Strategic Priorities at General Meeting
Trendline Trendline
Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis
Trendline Trendline
Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments

Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments

Lantern Pharma Receives FDA Approval for HARMONIC Phase 2 Trial Amendments
Trendline Trendline
CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development

CEL-SCI Reports Progress in Multikine Cancer Therapy Development